transmucosal

transmucosal

 [trans″mu-ko´sal]
entering through, or across, a mucous membrane, as the administration of a drug via the cavity between the cheek and gum.
References in periodicals archive ?
This report deals with transdermal drug delivery - an approach used to deliver drugs through the skin for therapeutic use as an alternative to oral,intravascular, subcutaneous and transmucosal routes.
Tonixs proprietary eutectic formulation of cyclobenzaprine, or TNX-102 SL, is designed for chronic sublingual (under-the-tongue) administration daily at bedtime, which facilitates transmucosal absorption of cyclobenzaprine and bypasses first pass liver metabolism.
Tonix's proprietary eutectic formulation of cyclobenzaprine, or TNX-102 SL, is designed for chronic sublingual (under-the-tongue) administration daily at bedtime, which facilitates transmucosal absorption of cyclobenzaprine and bypasses first pass liver metabolism.
Tonix's proprietary eutectic formulation of cyclobenzaprine, or TNX-102 SL, is designed for chronic sublingual administration daily at bedtime, which facilitates transmucosal absorption of cyclobenzaprine and bypasses first pass liver metabolism.
On 21 December 2018, the FDA had issued Braeburn a tentative approval of Brixadi for the treatment of moderate-to-severe opioid use disorder (OUD) in patients, who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
Absorption and bioavailability of oral transmucosal fentanyl citrate.
When combined with the right treatments and supports, novel formulations or delivery mechanisms described in the FDA guidance--including passive-compliance formulations such as sustained-release depots and implants--can provide effective treatment of OUD, and may result in less misuse, abuse, or accidental exposure compared to self-administered formulations such as transmucosal tablets and films.
It includes transmucosal buprenorphine, a commonly used medication to treat opioid addiction, and contingency management designed to provide incentives to reinforce positive behaviors.
Although the heterogeneity cannot currently be explained by SLIT tablet dose and treatment duration due to the results of the meta-regression, the different transmucosal concentration gradient may cause a significant difference even in patients undergoing a similar dose of SLIT tablets.[28] These findings suggest that in addition to the concentration of the extract, the biological activity of SLIT tablets, transmucosal diffusion gradient, and other parameters should also be evaluated as well as the SLIT tablets dose.[29] Moreover, the inclusion criteria of each RCT varied slightly from each other on characteristics, such as age range and dose of SLIT tablets, resulting in the relatively high heterogeneity.
[UKPRwire, Wed Oct 10 2018] TMR Research discusses the future of the global transdermal and transmucosal drug delivery system market in its latest report.
[ClickPress, Wed Oct 10 2018] TMR Research discusses the future of the global transdermal and transmucosal drug delivery system market in its latest report.
Though biopsy is used commonly to diagnose these intraoral lesions, but it requires anaesthesia and pose problems in diagnosing the transmucosal lesions.